Who are CaCP29's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): KK8398, EN3267, Veopoz, AVACINCAPTAD PEGOL SODIUM, Ultomiris, H5G1.1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cacp29.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CaCP29 — Competitive Intelligence Brief

CaCP29 (CaCP29) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement inhibitor. Area: Immunology.

phase 2 Complement inhibitor C5aR1 Immunology Biologic Live · refreshed every 30 min

Target snapshot

CaCP29 (CaCP29) — InflaRx GmbH. CaCP29 is a monoclonal antibody targeting the complement system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CaCP29 TARGET	CaCP29	InflaRx GmbH	phase 2	Complement inhibitor	C5aR1
KK8398	KK8398	Kyowa Kirin Co., Ltd.	phase 3	Complement C5a receptor antagonist	C5aR1 (C5a receptor 1)
EN3267	EN3267	Kyowa Kirin Co., Ltd.	phase 3	C5a receptor antagonist	C5aR1 (C5a receptor 1)
Veopoz	POZELIMAB	Regeneron	marketed	Complement Inhibitor [EPC]	Complement C5	2023-01-01
AVACINCAPTAD PEGOL SODIUM	AVACINCAPTAD PEGOL SODIUM		marketed	Complement Inhibitors	Complement C5	2023-01-01
Ultomiris	RAVULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	Complement C5	2018-01-01
H5G1.1	ECULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	C5	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-11 — AVACINCAPTAD PEGOL SODIUM · 8236773 · Method of Use · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 9617546 · Compound · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 7579456 · Compound · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11491176 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11273171 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 12016875 · Method of Use · US

Sponsor landscape (Complement inhibitor class)

CSL Behring · 3 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Aldeyra Therapeutics, Inc. · 1 drug in this class
BioCryst Pharmaceuticals · 1 drug in this class
Haaglanden Medical Centre · 1 drug in this class
InflaRx GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CaCP29 — Competitive Intelligence Brief. https://druglandscape.com/ci/cacp29. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab